TrialThe oncologist2019

Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Aaron R Hansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.